nifedipine has been researched along with Cognitive Decline in 2 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dyer, AH | 1 |
Murphy, C | 1 |
Segurado, R | 2 |
Lawlor, B | 2 |
Kennelly, SP | 1 |
Kennelly, S | 1 |
Olde Rikkert, MGM | 1 |
Howard, R | 1 |
Pasquier, F | 1 |
Börjesson-Hanson, A | 1 |
Tsolaki, M | 1 |
Lucca, U | 1 |
Molloy, DW | 1 |
Coen, R | 1 |
Riepe, MW | 1 |
Kálmán, J | 1 |
Kenny, RA | 1 |
Cregg, F | 1 |
O'Dwyer, S | 1 |
Walsh, C | 1 |
Adams, J | 1 |
Banzi, R | 1 |
Breuilh, L | 1 |
Daly, L | 1 |
Hendrix, S | 1 |
Aisen, P | 1 |
Gaynor, S | 1 |
Sheikhi, A | 1 |
Taekema, DG | 1 |
Verhey, FR | 1 |
Nemni, R | 1 |
Nobili, F | 1 |
Franceschi, M | 1 |
Frisoni, G | 1 |
Zanetti, O | 1 |
Konsta, A | 1 |
Anastasios, O | 1 |
Nenopoulou, S | 1 |
Tsolaki-Tagaraki, F | 1 |
Pakaski, M | 1 |
Dereeper, O | 1 |
de la Sayette, V | 1 |
Sénéchal, O | 1 |
Lavenu, I | 1 |
Devendeville, A | 1 |
Calais, G | 1 |
Crawford, F | 1 |
Mullan, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 trials available for nifedipine and Cognitive Decline
Article | Year |
---|---|
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili | 2020 |
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease | 2018 |